The BLMH Knockout Jurkat Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Jurkat human T lymphocyte cell line. This model features targeted disruption of the BLMH gene, which encodes bleomycin hydrolase, a cysteine protease involved in drug metabolism and peptide processing. The polyclonal format provides a pooled population of edited cells, enabling robust functional studies without clonal selection biases. This loss-of-function model is suitable for investigating BLMH-dependent pathways in a well-characterized T-cell leukemia background.
The Jurkat cell line is an immortalized T lymphocyte model derived from the peripheral blood of a patient with acute T-cell leukemia. Jurkat cells are widely used to study T-cell signaling, apoptosis, and leukemia biology. Their rapid growth and well-defined signaling networks make them an ideal host for knockout studies aimed at dissecting molecular mechanisms of chemoresistance, antigen processing, and proteasomal degradation.
BLMH encodes a cysteine protease that acts as a bleomycin hydrolase, inactivating the anticancer antibiotic bleomycin through hydrolytic cleavage, thereby conferring drug resistance. The enzyme is regulated by NRF2 and is transcriptionally activated upon bleomycin exposure. Downstream, BLMH decycles homocysteine-thiolactone, protecting against its toxicity, and degrades amyloid-beta peptides, linking it to Alzheimer??s disease pathology. BLMH interacts with the 20S proteasome, MHC class I molecules, and heat shock proteins, positioning it at the intersection of protein catabolism and antigen presentation.
In the Jurkat T-cell context, BLMH disruption provides a valuable tool for studying chemoresistance mechanisms, as Jurkat cells naturally express this enzyme and are sensitive to bleomycin-induced DNA damage. Loss of BLMH function is expected to enhance bleomycin cytotoxicity, making this model useful for drug sensitivity profiling. Additionally, because Jurkat cells are involved in immune processes, BLMH knockout may impact MHC class I antigen presentation and proteasomal degradation, offering insights into immunoproteasome biology and T-cell-mediated responses.
This polyclonal knockout cell population is suitable for a range of applications, including bleomycin toxicity assays, homocysteine-thiolactone hydrolase activity measurements, and amyloid-beta clearance studies. Researchers can employ Western blotting to confirm BLMH protein loss, flow cytometry to assess drug-induced apoptosis, and functional assays to evaluate downstream effects on proteasome substrates. The model also enables investigation of the NRF2/BLMH axis and its role in oxidative stress responses. For additional technical information or customization options, please contact Ascent Research.
